GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Cingulate Inc.
The stock price of Cingulate, a biotech company developing drugs for ADHD, reflects its efforts to bring products with improved delivery to market. Its price trajectory is a classic biotech story, with valuation driven by clinical trial results.
Share prices of companies in the market segment - Pharma psycho
Cingulate Inc. is a biopharmaceutical company developing drugs with innovative delivery technology for the treatment of attention deficit hyperactivity disorder (ADHD). We have classified it in the Pharma: Psychology category. The chart below shows how the market is evaluating new approaches to treating mental disorders.
Broad Market Index - GURU.Markets
Cingulate is a pharmaceutical company developing long-acting medications for the treatment of attention deficit hyperactivity disorder (ADHD). As an innovator, it is included in our GURU.Markets index. The chart below shows the overall market trend. Compare it with Cingulate's performance to assess the state of this sector.
Change in the price of a company, segment, and market as a whole per day
CING - Daily change in the company's share price Cingulate Inc.
Cingulate Inc.'s daily stock price fluctuations reflect the extreme volatility inherent in biotech companies. This metric measures the company's sensitivity to news about clinical trials of its ADHD drugs.
Daily change in the price of a set of shares in a market segment - Pharma psycho
Cingulate Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with CING, which focuses on ADHD treatments, helps to assess it as a high-risk, clinically data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Cingulate develops medications for the treatment of ADHD using delayed-release technology. The company's shares are highly volatile and driven by news of clinical trials. This hope-driven dynamic contributes to the overall market "noise."
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Cingulate Inc.
Cingulate Inc.'s year-over-year performance is a story of developing a new generation of ADHD medications. Its 12-month market cap depends entirely on progress in clinical trials of its extended-release medications. Success could offer patients a more convenient dosing regimen, which would become its key competitive advantage.
Annual dynamics of market capitalization of the market segment - Pharma psycho
As an early-stage biotech, Cingulate is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news about clinical trials of its ADHD drugs. Its stock price will reflect investors' speculative beliefs.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Shares of Cingulate, which is developing ADHD drugs, are a pure bet on success in clinical trials. Their performance relative to the market reflects investor expectations for a particular drug. The stock's trajectory is determined entirely by lab news, not the state of the economy.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Cingulate Inc.
Cingulate is a biopharmaceutical company developing drugs for the treatment of ADHD. Its monthly performance is entirely dependent on progress in its clinical programs. News about trial results and interactions with the FDA regarding its drugs are key events for its valuation.
Monthly dynamics of market capitalization of the market segment - Pharma psycho
This chart reflects the dynamics of the biotech sector. For Cingulate, a clinical-stage company, it's the backdrop. Its volatile movements demonstrate how investor expectations surrounding the results of its ADHD drug trials are impacting the entire industry.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Biotech stocks, especially early-stage ones, live in a world of their own, dominated by clinical trial data. The chart below shows the overall market sentiment. Is Cingulate Inc. following this trend, or is news about its ADHD drug development creating a completely separate narrative?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Cingulate Inc.
Cingulate, which develops ADHD treatments using its innovative delivery technology, is extremely news-sensitive. Its weekly stock price is a direct reaction to clinical trial data and FDA decisions regarding its delayed- and extended-release medications.
Weekly dynamics of market capitalization of the market segment - Pharma psycho
Cingulate operates in the highly competitive psychiatry sector, where investor sentiment drives global sentiment. The success or failure of a major blockbuster drug influences expectations for all companies in the niche. The chart below shows how CING fares in this competitive landscape compared to other developers.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Cingulate Inc., as a biotech company, often ignores broader market trends. Its fate depends not on GDP or inflation, but on the results of clinical trials. The chart below clearly demonstrates how CING shares can rise or fall on news releases while the overall market moves in a different direction.
Market capitalization of the company, segment and market as a whole
CING - Market capitalization of the company Cingulate Inc.
Cingulate's market cap reflects its efforts to improve ADHD treatment. The company is developing extended-release medications. Its valuation chart reflects how investors view this technology and its chances of gaining regulatory approval and competing with existing drugs.
CING - Share of the company's market capitalization Cingulate Inc. within the market segment - Pharma psycho
Cingulate Inc. develops medications for attention deficit hyperactivity disorder (ADHD) using its precision-timed drug delivery technology. Its market share in the pharmaceutical sector is based on this innovative approach. The graph shows how its once-daily pills can be used by patients.
Market capitalization of the market segment - Pharma psycho
Cingulate Inc. is developing ADHD medications using technology that ensures their effectiveness throughout the day. The chart below shows the market capitalization of the psychopharmaceutical sector. This represents a market seeking more convenient and effective solutions for patients.
Market capitalization of all companies included in a broad market index - GURU.Markets
Cingulate develops ADHD treatments using its precision-delivery technology. Its market cap is a bet on more convenient therapy. The chart below shows the economic weight of companies improving existing treatments.
Book value capitalization of the company, segment and market as a whole
CING - Book value capitalization of the company Cingulate Inc.
Cingulate's book value is capital for ADHD drug development. Its foundation consists of the intellectual property for its precision-timed drug delivery (PTAB) technology and cash for clinical trials of its drug candidates. The chart below shows how the company utilizes its resources to develop next-generation drugs.
CING - Share of the company's book capitalization Cingulate Inc. within the market segment - Pharma psycho
Cingulate Inc., which develops drugs for the central nervous system, has key assets in the form of R&D laboratories. The S_BCap_Seg graph shows its share of scientific infrastructure, reflecting its focus on psychopharmacology research.
Market segment balance sheet capitalization - Pharma psycho
Cingulate is developing ADHD treatments using its precision drug delivery technology. Its value lies in this platform and its patents. A book value chart shows that its assets are almost entirely intangible, which is typical for a pharmaceutical company in the R&D stage.
Book value of all companies included in the broad market index - GURU.Markets
Cingulate's book value lies in its technology for improving ADHD therapy. The company's assets consist of the rights to its drug delivery platform and capital for clinical trials. This capital base is aimed at developing drugs for the treatment of attention deficit disorder that work throughout the day after a single dose.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Cingulate Inc.
Cingulate is developing medications for ADHD using its precision-timed delivery technology. Its book value is low. Its market capitalization reflects investors' bet that its innovative drug delivery method will provide significant advantages over existing therapies.
Market to book capitalization ratio in a market segment - Pharma psycho
Cingulate Inc. develops drugs to treat ADHD using its drug delivery technology. The company's value lies in its patents. The chart shows how the market values its innovative approach to treating this common disorder compared to its tangible assets.
Market to book capitalization ratio for the market as a whole
Cingulate develops drugs for the treatment of ADHD using its innovative drug delivery technology. The company's value lies in this platform technology. The chart shows how the market views the potential for improving existing treatments, rather than developing entirely new molecules.
Debts of the company, segment and market as a whole
CING - Company debts Cingulate Inc.
Cingulate, a pharmaceutical company developing extended-release ADHD medications, is using debt to finance its clinical trials. This chart shows how the company is raising capital to complete the final stages of development and prepare for FDA submission. Debt is a bridge to eventual market entry.
Market segment debts - Pharma psycho
Cingulate is developing medications for ADHD (attention deficit hyperactivity disorder) using its precision drug delivery technology throughout the day. As a clinical-stage company, it relies entirely on external funding. This chart shows its financial status and ability to continue clinical development.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Cingulate Inc.
Cingulate is a biopharmaceutical company developing drugs to treat attention deficit hyperactivity disorder (ADHD). This chart shows its reliance on debt. For a company operating in an established market with large competitors, debt may be necessary for clinical trials and marketing.
Market segment debt to market segment book capitalization - Pharma psycho
Cingulate Inc. is developing drugs for ADHD using delayed-release technology. This pharmaceutical industry chart reflects how companies fund research in niche areas. It provides context for assessing the company's financial strategy during the commercialization of its key product.
Debt to book value of all companies in the market
Cingulate Inc. is a biopharmaceutical company developing drugs with an innovative delivery system for the treatment of ADHD. The debt-to-book ratio reflects the overall risk appetite of investors in the pharmaceutical industry. Cingulate's success depends on the availability of capital to conduct costly clinical trials and bring the product to market.
P/E of the company, segment and market as a whole
P/E - Cingulate Inc.
Cingulate develops medications for attention deficit hyperactivity disorder (ADHD) using its precision-timed drug delivery technology. This graph reflects the potential for improving ADHD treatment. Its significance demonstrates the investors' belief that their drugs will offer significant advantages over existing medications.
P/E of the market segment - Pharma psycho
Cingulate Inc. is a biotech company. This chart shows the average P/E ratio for the biotech sector. Comparing the company's P/E to this benchmark allows us to understand how highly the market values its ADHD drug delivery technology compared to the average prospects of other biotech companies.
P/E of the market as a whole
Cingulate is a biopharmaceutical company developing medications for ADHD using its precision-timed drug delivery technology. This chart shows sentiment in the pharmaceutical sector. The company's valuation depends on the success of its clinical programs and the ability to demonstrate the superiority of its delivery technology over existing drugs.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Cingulate Inc.
Cingulate Inc. is a biopharmaceutical company developing medications for ADHD using its precision-timed drug delivery technology. The chart shows future revenue expectations, which depend on the success of clinical trials and the company's ability to compete in the large and saturated ADHD market.
%20P%2FE%20Cingulate%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Cingulate-Inc.&v=1772519269049 "Chart of the company's future (projected) P/E Cingulate Inc.")
Future (projected) P/E of the market segment - Pharma psycho
Cingulate Inc. develops pharmaceuticals using its precision-timed delivery technology, primarily for the treatment of ADHD. This chart shows how its future revenue expectations compare to the industry average, reflecting the potential of its platform to improve existing treatments.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-psycho&v=1772519269118 "Future (projected) P/E graph of the market segment - Pharma psycho")
Future (projected) P/E of the market as a whole
Cingulate Inc. is a biopharmaceutical company developing medications with innovative delivery technology for the treatment of ADHD. Its goal is to offer patients a more convenient medication regimen. Success depends on trial results and the company's ability to compete with existing medications.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772519269190 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Cingulate Inc.
Cingulate Inc. is a biopharmaceutical company using its technology platform to develop controlled-release medications, primarily for the treatment of attention deficit hyperactivity disorder (ADHD). While in the development stage, it incurs significant R&D expenditures. This chart reflects investments in the development of improved dosage forms.
Profit of companies in the market segment - Pharma psycho
Cingulate Inc. is a biopharmaceutical company using its precision drug delivery technology to develop treatments for attention deficit hyperactivity disorder (ADHD). This chart shows the profitability of its segment. Cingulate's success depends on its ability to offer a more convenient dosing regimen than existing drugs, which could disrupt the market.
Overall market profit
Cingulate Inc. is a biopharmaceutical company developing drugs with innovative delivery technology for the treatment of ADHD. Its success depends on the results of clinical trials and its ability to compete in an existing market. This chart illustrates the overall economic trends against which Cingulate is attempting to carve out a niche through its technological advantage.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Cingulate Inc.
Cingulate Inc. develops pharmaceuticals using its precision-timed delivery technology, primarily for the treatment of ADHD. This graph reflects analysts' expectations for future revenue, which depend on the success of clinical trials and the ability to demonstrate the superiority of its technology over existing medications.
%20profit%20of%20the%20company%20Cingulate%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Cingulate-Inc.&v=1772519269400 "Graph of future (projected) profit of the company Cingulate Inc.")
Future (predicted) profit of companies in the market segment - Pharma psycho
Cingulate Inc. is a biopharmaceutical company using its platform to develop controlled-release medications, primarily for the treatment of ADHD. This chart shows revenue projections for the psychopharmacology segment. It reflects expectations for innovative dosage forms that improve patient convenience.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-psycho&v=1772519269493 "Graph of future (predicted) profits of companies in a market segment - Pharma psycho")
Future (predicted) profit of the market as a whole
Cingulate Inc. is developing ADHD medications with a unique delivery system. Their success depends on regulatory approval and the ability to commercialize the product. The overall market revenue forecast impacts the investment climate, which determines how easily the company will be able to raise funds for marketing and sales.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772519269524 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Cingulate Inc.
Cingulate Inc. is a biopharmaceutical company developing drugs with an innovative delivery system for the treatment of ADHD. Currently in the clinical stage, it has no revenue. P/S will be important after market launch to assess the marketability of its technology.
P/S market segment - Pharma psycho
Cingulate Inc. is a biopharmaceutical company developing treatments for attention deficit hyperactivity disorder (ADHD) using its precision-timed drug delivery technology. This chart reflects how the market views their innovative technology and its potential in the large and established ADHD treatment market.
P/S of the market as a whole
Cingulate Inc. develops medications for attention deficit hyperactivity disorder (ADHD) using its precision-timed drug release technology. There is no revenue, and the company's valuation is dependent on the success of clinical trials. This chart, showing actual revenue estimates, highlights the speculative nature of investing in Cingulate.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Cingulate Inc.
Cingulate Inc. is a biopharmaceutical company developing medications for attention deficit hyperactivity disorder (ADHD) using its precision drug delivery technology. This chart reflects investor expectations for future revenue from its innovative formulas, which promise a more convenient dosing regimen.
%20P%2FS%20Cingulate%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Cingulate-Inc.&v=1772519269657 "The graph of the company's future (projected) P/S Cingulate Inc.")
Future (projected) P/S of the market segment - Pharma psycho
Cingulate Inc. is a clinical-stage biopharmaceutical company developing drugs for the treatment of attention deficit hyperactivity disorder (ADHD) using its precision drug delivery technology. This chart shows how the market perceives the future potential of its advanced formulations, comparing it to other companies in the psychopharmacology field.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-psycho&v=1772519269669 "Future (projected) P/S market segment graph - Pharma psycho")
Future (projected) P/S of the market as a whole
Cingulate Inc. develops medications for the treatment of attention deficit hyperactivity disorder (ADHD) using its proprietary drug delivery technology. This chart illustrates overall revenue expectations, and CING demonstrates how innovations in drug delivery methods for existing medications can create new products and improve patients' quality of life.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772519269683 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Cingulate Inc.
Cingulate Inc. is a clinical-stage biopharmaceutical company using its proprietary technology to develop extended-release medications for the treatment of attention deficit hyperactivity disorder (ADHD). The company currently has no commercial products, so sales revenue is not included in this chart.
Sales of companies in the market segment - Pharma psycho
Cingulate Inc. is a biopharmaceutical company developing drugs with an innovative delivery system for the treatment of ADHD. Currently, it has no product revenue. The graph may reflect collaboration revenue, which funds its clinical development.
Overall market sales
Cingulate Inc. is a biopharmaceutical company developing medications for the treatment of attention deficit hyperactivity disorder (ADHD). Demand for these medications is driven by demographics and diagnosis rates. This overall economic outlook has little impact on Cingulate, as ADHD treatment is a medical necessity for many patients.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Cingulate Inc.
Cingulate is a biopharmaceutical company developing treatments for attention deficit hyperactivity disorder (ADHD) using its precision drug delivery technology. Its revenue forecast is dependent on the success of clinical trials. This chart reflects analyst expectations for its innovative approaches to ADHD treatment.
%20sales%20of%20the%20company%20Cingulate%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Cingulate-Inc.&v=1772519269772 "Schedule of future (projected) sales of the company Cingulate Inc.")
Future (projected) sales of companies in the market segment - Pharma psycho
Cingulate Inc. is a biopharmaceutical company developing treatments for attention deficit hyperactivity disorder (ADHD). This chart shows projected revenue for the psychopharmaceutical segment. It helps estimate potential demand for drugs with improved performance, which is the core of Cingulate's product strategy.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-psycho&v=1772519269794 "Schedule of future (projected) sales of companies in the market segment - Pharma psycho")
Future (projected) sales of the market as a whole
Cingulate Inc. is a biopharmaceutical company developing drugs with an innovative delivery system for the treatment of ADHD. The company's success depends on clinical trial results and market competition. This graph of overall market expectations reflects the investment climate, which is important for funding R&D and commercializing new drug formulations.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772519269828 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Cingulate Inc.
Cingulate Inc. is a biopharmaceutical company developing drugs with an innovative delivery system for the treatment of ADHD. This chart reflects the company's current status in clinical trials. It demonstrates the company's investment in research, the success of which determines its future.
Market segment marginality - Pharma psycho
Cingulate Inc. is a biopharmaceutical company using its proprietary technology platform to develop drugs for the treatment of attention deficit hyperactivity disorder (ADHD). This chart shows the average profit margin in the psychopharmacology sector. It helps assess the commercial advantage Cingulate's technology could provide compared to existing drugs.
Market marginality as a whole
Cingulate Inc. is a biopharmaceutical company developing treatments for attention deficit hyperactivity disorder (ADHD) using its precision drug delivery technology. This overall revenue chart doesn't reflect the specifics of its business, which is focused on improving existing treatments in a large and established market.
Employees in the company, segment and market as a whole
Number of employees in the company Cingulate Inc.
Cingulate Inc. is a biopharmaceutical company developing drugs for the treatment of ADHD using its precision drug delivery technology. Its small team is focused on conducting clinical trials. This chart shows the size of the research team working to improve the therapy for a wide range of patients.
Share of the company's employees Cingulate Inc. within the market segment - Pharma psycho
Cingulate Inc. is a biopharmaceutical company developing drugs for attention deficit hyperactivity disorder (ADHD) using its precision delivery technology. This chart illustrates its innovative approach. It shows the proportion of pharmaceutical chemists and clinicians working on long-acting medications that Cingulate brings together.
Number of employees in the market segment - Pharma psycho
Cingulate Inc. is a biopharmaceutical company developing drugs with innovative delivery technology for the treatment of ADHD. This chart shows its work in psychopharmacology. Growth in this field reflects the search for more convenient and effective dosage forms that can improve patient compliance and ensure a stable therapeutic effect.
Number of employees in the market as a whole
Cingulate Inc. is a biopharmaceutical company developing medications for the treatment of attention deficit hyperactivity disorder (ADHD). Psychopharmacology is an important and growing sector. This graph illustrates overall employment, and innovations in this field are responding to the growing public demand for mental health solutions.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Cingulate Inc. (CING)
Cingulate Inc. develops new forms of drug delivery. This is a pharmaceutical innovation based on engineering. This chart shows how the market values this specific intellectual capital. The high cost per employee represents a premium for technology that can improve existing drugs and extend their patents.
%20of%20the%20company%20Cingulate%20Inc.%20(CING)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Cingulate-Inc.-CING&v=1772519269992 "Chart of market capitalization per employee (in thousands of dollars) of the company Cingulate Inc. (CING)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma psycho
Cingulate Inc. is developing medications for ADHD using its precision drug delivery technology. The company's market capitalization per employee reflects the market valuation of this innovative platform. A high value indicates investors' confidence in its potential to improve existing treatments.
%20by%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-psycho&v=1772519270032 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma psycho")
Market capitalization per employee (in thousands of dollars) for the overall market
Cingulate Inc. is a biopharmaceutical company developing treatments for attention deficit hyperactivity disorder (ADHD) using its precision drug delivery technology. This chart reflects how the market views the potential of this technology and the team's ability to develop an improved version of the therapy for a larger market.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772519270050 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Cingulate Inc. (CING)
Cingulate is a biotech company that doesn't create new molecules, but rather develops improved (extended-release) delivery systems for existing drugs (for example, for ADHD). This is an R&D business. This negative graph shows how much capital is "burned" per scientist in the process of creating these "improved" versions.
%20Chart%20Cingulate%20Inc.%20(CING)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Cingulate-Inc.-CING&v=1772519270068 "Company Profit Per Employee (in thousands of dollars) Chart Cingulate Inc. (CING)")
Profit per employee (in thousands of dollars) in the market segment - Pharma psycho
Cingulate Inc. is a biopharmaceutical company using its Precision Timed Release™ platform to develop once-daily ADHD medications. This graph highlights the value of their drug delivery technology. It illustrates how innovation in drug delivery can create a product with high commercial value and, consequently, high profit potential.
%20in%20the%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-psycho&v=1772519270089 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma psycho")
Profit per employee (in thousands of dollars) for the market as a whole
Cingulate Inc. is a biopharmaceutical company developing controlled-release medications for the treatment of ADHD. Their Precision Timed Release (PTR) technology is key. This chart shows R&D expenditure per employee. It reflects how much the company invests in the development and clinical trials of its innovative formulations.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772519270118 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Cingulate Inc. (CING)
Cingulate Inc. is a biopharmaceutical company developing drugs for the treatment of ADHD. This graph does not reflect commercial activity during the clinical trials stage. It illustrates investment in research. Success in development and the launch of a new product will lead to a sharp increase in this indicator.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Cingulate-Inc.-CING&v=1772519270130 "Sales chart per company employee Cingulate Inc. (CING)")
Sales per employee in the market segment - Pharma psycho
Cingulate (CING) is a biopharmaceutical company using its Precision Timed Release™ drug delivery technology to develop treatments for ADHD (attention deficit disorder). This chart shows the average revenue per employee in the pharmaceutical segment. Being in the R&D stage, Cingulate has no commercial sales. Comparison to the benchmark highlights their focus on development.
Sales per employee for the market as a whole
Cingulate (CING) is a biotech company developing ADHD medications with a specialized delivery system (long-acting). They are a clinical-stage R&D company with no revenue. This metric is irrelevant. Their entire value lies in the potential of their delivery technology and the success of their clinical trials.
Short shares by company, segment and market as a whole
Shares shorted by company Cingulate Inc. (CING)
Cingulate Inc. is a biotech company using its precision timed release technology to create once-daily ADHD drugs. This chart shows the bets that their technology is useless. The bears believe the ADHD market is already saturated, and their drug will have no commercial advantage.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Cingulate-Inc.-CING&v=1772519270299 "Short Shares Chart for the Company Cingulate Inc. (CING)")
Shares shorted by market segment - Pharma psycho
Cingulate (CING) is a biotech that doesn't create new molecules, but rather improves the delivery of existing ADHD medications (similar to Ritalin). This chart highlights the pessimism in the sector. The growing short position in the industry is a bet that this technology is unnecessary. Investors doubt that doctors and insurers will choose CING's "improved" generic version over existing, cheaper alternatives.
Shares shorted by the overall market
Cingulate (CING) is a clinical-stage biotech. Its value reflects the hope for future success. When this indicator of overall pessimism rises, investors are less inclined to hope. They are dumping unprofitable companies en masse that require refinancing.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Cingulate Inc. (CING)
Cingulate develops medications for ADHD using its sustained drug delivery technology. It's a highly specialized pharmaceutical company. This oscillator tracks the FDA approval "pulse." It "warms up" with positive clinical trial data and "cools down" during the long months of waiting for regulatory decisions.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Cingulate-Inc.-CING&v=1772519270521 "RSI 14 indicator chart for the company's stock Cingulate Inc. (CING)")
RSI 14 Market Segment - Pharma psycho
Cingulate is a biopharmaceutical company specializing in the treatment of ADHD. Their CTx-1301 technology (based on dexmethylphenidate) uses their Precision Timed Release platform to deliver the drug throughout the day. This chart reflects the overall sentiment in the psychopharmacology sector, helping to assess how the market views this speculative field.
RSI 14 for the overall market
Cingulate (CING) is a biotech R&D company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast CING (Cingulate Inc.)
Cingulate (CING) is a biopharmaceutical company developing ADHD treatments using its precision-timed delivery technology. This chart shows the average 12-month analyst forecast, reflecting their collective belief that Cingulate's innovative platform will successfully complete clinical trials and compete in the mature ADHD market.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-CING-Cingulate-Inc.&v=1772519270636 "A chart showing analyst consensus forecasts for the expected stock price. CING (Cingulate Inc.)")
The difference between the consensus estimate and the actual stock price CING (Cingulate Inc.)
Cingulate is a biopharmaceutical company developing drugs (CTx-1301) for ADHD using its precision delivery technology. It's a risky bet on R&D. This chart shows how far the current stock price differs from the "fair" value predicted by analysts. This gap essentially reflects the experts' belief that their drug candidates will successfully complete clinical trials and be approved by the FDA.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-CING-Cingulate-Inc.&v=1772519270678 "A chart showing the difference between the consensus forecast and the actual stock price. CING (Cingulate Inc.)")
Analyst consensus forecast for stock prices by market segment - Pharma psycho
Cingulate is a biotech company challenging the ADHD market. The company is developing drugs with a new delivery technology to improve treatment. This chart reflects analysts' overall expectations for the entire psychopharma sector. It shows whether experts believe this highly competitive market will grow or whether they consider it saturated.
Analysts' consensus forecast for the overall market share price
Cingulate is a biotech company developing drugs (based on its platform) for the treatment of central nervous system disorders, such as ADHD. This is a high-risk sector, where success depends on clinical trial results. This chart reflects the overall risk appetite in the market. For Cingulate, which has yet to generate revenue, overall analyst optimism (the rising chart) is critical for raising capital.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Cingulate Inc.
Cingulate is a biotech company working on the Holy Grail of ADHD: a triple-release pill (CTx-1301) that's designed to last all day. Their business is R&D, with binary risk. This chart is a summary indicator of their trajectory. It doesn't reflect profit (there aren't any), but a speculative assessment of their clinical data, their chances of FDA approval, and their race to keep up with the money.
AKIMA Market Segment Index - Pharma psycho
Cingulate (CING) is challenging the massive ADHD market using its Precision Timed Release (PTR) platform, which aims to create a once-daily medication. This is a high-risk strategy in psychopharmaceuticals. The chart below shows the average composite index for the entire segment. By comparing Cingulate to this industry benchmark, investors can assess how the market views CING's approach.
The AKIM Index for the overall market
Cingulate is a biopharmaceutical company using precision delivery technology (PTR) to develop long-acting ADHD medications. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this improvement in existing medications compares to overall economic trends.
